

TABLE REFERENCES

1. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. *J Infect Dis* 2002;186 Suppl 1:S3-28.
2. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. *N Engl J Med* 2002;347(21):1652-1661.
3. Mihret W, Rinke de Wit TF, Petros B, et al. Herpes simplex virus type 2 seropositivity among urban adults in Africa: results from two cross-sectional surveys in Addis Ababa, Ethiopia. *Sex Transm Dis* 2002;29(3):175-81.
4. Ndjoyi-Mbiguino A, Ozouaki F, Legoff J, et al. Comparison of washing and swabbing procedures for collecting genital fluids to assess cervicovaginal shedding of herpes simplex virus type 2 DNA. *J Clin Microbiol* 2003;41(6):2662-4.
5. Hogrefe W, Su X, Song J, Ashley R, Kong L. Detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in African sera by using recombinant gG2, Western blotting, and gG2 inhibition. *J Clin Microbiol* 2002;40(10):3635-40.
6. Sutcliffe S, Taha TE, Kumwenda NI, Taylor E, Liomba GN. HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus, and hepatitis B virus infections among male workers at a sugar estate in Malawi. *J Acquir Immune Defic Syndr* 2002;31(1):90-7.
7. Eltom MA, Mbulaiteye SM, Dada AJ, Whitby D, Biggar RJ. Transmission of human herpesvirus 8 by sexual activity among adults in Lagos, Nigeria. *Aids* 2002;16(18):2473-2478.
8. Mwansasu A, Mwakagile D, Haarr L, Langeland N. Detection of HSV-2 in genital ulcers from STD patients in Dar es Salaam, Tanzania. *J Clin Virol* 2002;24(3):183-92.
9. Kapiga SH, Sam NE, Shao JF, et al. Herpes simplex virus type 2 infection among bar and hotel workers in northern Tanzania: prevalence and risk factors. *Sex Transm Dis* 2003;30(3):187-92.
10. Msuya SE, Mbizvo E, Hussain A, Sam NE, Jeansson S, Stray-Pedersen B. Seroprevalence and correlates of herpes simplex virus type 2 among urban Tanzanian women. *Sex Transm Dis* 2003;30(7):588-92.
11. Kamali A, Quigley M, Nakiyingi J, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: A community randomised trial. *Lancet* 2003;361(9358):645-652.

12. Mbizvo EM, Msuya Sia E, Stray-Pedersen B, Chirenje MZ, Munjoma M, Hussain A. Association of herpes simplex virus type 2 with the human immunodeficiency virus among urban women in Zimbabwe. *Int J STD AIDS* 2002;13(5):343-8.
13. Castle PE, Escoffery C, Schachter J, et al. Chlamydia trachomatis, herpes simplex virus 2, and human T-cell lymphotropic virus type 1 are not associated with grade of cervical neoplasia in Jamaican colposcopy patients. *Sex Transm Dis* 2003;30(7):575-80.
14. Uribe-Salas F, Conde-Glez CJ, Juarez-Figueroa L, Hernandez-Castellanos A. Sociodemographic dynamics and sexually transmitted infections in female sex workers at the Mexican-Guatemalan border. *Sex Transm Dis* 2003;30(3):266-271.
15. Abraham CD, Conde-Glez CJ, Cruz-Valdez A, Sanchez-Zamorano L, Hernandez-Marquez C, Lazcano-Ponce E. Sexual and demographic risk factors for herpes simplex virus type 2 according to schooling level among Mexican youths. *Sex Transm Dis* 2003;30(7):549-55.
16. Conde-Glez CJ, Juarez-Figueroa L, Uribe-Salas F, et al. Analysis of herpes simplex virus 1 and 2 infection in women with high risk sexual behaviour in Mexico. *Int J Epidemiol* 1999;28(3):571-6.
17. Smith JS, Herrero R, Bosetti C, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. *J Natl Cancer Inst* 2002;94(21):1604-13.
18. Robinson LG, Black FL, Lee FK, et al. Helicobacter pylori prevalence among indigenous peoples of South America. *J Infect Dis* 2002;186(8):1131-1137.
19. Howard M, Sellors JW, Jang D, et al. Regional distribution of antibodies to herpes simplex virus type 1 (HSV-1) and HSV-2 in men and women in Ontario, Canada. *J Clin Microbiol* 2003;41(1):84-9.
20. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE. A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. *N Engl J Med* 1999;341(19):1432-8.
21. Corey L, Langenberg AG, Ashley R, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. *Jama* 1999;282(4):331-40.

22. Xu F, Schillinger JA, Sternberg MR, et al. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. *J Infect Dis* 2002;185(8):1019-24.
23. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. *N Engl J Med* 1997;337(16):1105-11.
24. Renzi C, Douglas JM, Jr., Foster M, et al. Herpes simplex virus type 2 infection as a risk factor for human immunodeficiency virus acquisition in men who have sex with men. *J Infect Dis* 2003;187(1):19-25.
25. Stover CT, Smith DK, Schmid DS, et al. Prevalence of and risk factors for viral infections among human immunodeficiency virus (HIV)-infected and high-risk HIV-uninfected women. *J Infect Dis* 2003;187(9):1388-1396.
26. Gottlieb SL, Douglas JM, Jr., Schmid DS, et al. Seroprevalence and correlates of herpes simplex virus type 2 infection in five sexually transmitted-disease clinics. *J Infect Dis* 2002;186(10):1381-9.
27. Austin H, Macaluso M, Nahmias A, et al. Correlates of herpes simplex virus seroprevalence among women attending a sexually transmitted disease clinic. *Sex Transm Dis* 1999;26(6):329-34.
28. Frenkel LM, Garratty EM, Shen JP, Wheeler N, Clark O, Bryson YJ. Clinical reactivation of herpes simplex virus type 2 infection in seropositive pregnant women with no history of genital herpes. *Ann Intern Med* 1993;118(6):414-8.
29. Bryson Y, Dillon M, Bernstein DI, Radolf J, Zakowski P, Garratty E. Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. *J Infect Dis* 1993;167(4):942-6.
30. Turner KR, McFarland W, Kellogg TA, et al. Incidence and prevalence of herpes simplex virus type 2 infection in persons seeking repeat HIV counseling and testing. *Sex Transm Dis* 2003;30(4):331-4.
31. Siegel D, Golden E, Washington AE, et al. Prevalence and correlates of herpes simplex infections. The population-based AIDS in Multiethnic Neighborhoods Study. *Jama* 1992;268(13):1702-8.
32. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. *Ann Intern Med* 1992;116(3):197-202.

33. Mertz GJ, Ashley R, Burke RL, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. *J Infect Dis* 1990;161(4):653-60.
34. Lewis LM, Bernstein DI, Rosenthal SL, Stanberry LR. Seroprevalence of herpes simplex virus-type 2 in African-American college women. *J Natl Med Assoc* 1999;91(4):210-2.
35. Chernes TL, Meyn LA, Krohn MA, Hillier SL. Risk factors for infection with herpes simplex virus type 2: Role of smoking, douching, uncircumcised males, and vaginal flora. *Sex Transm Dis* 2003;30(5):405-410.
36. Breinig MK, Kingsley LA, Armstrong JA, Freeman DJ, Ho M. Epidemiology of genital herpes in Pittsburgh: serologic, sexual, and racial correlates of apparent and inapparent herpes simplex infections. *J Infect Dis* 1990;162(2):299-305.
37. Ross MW, Hwang LY, Zack C, Bull L, Williams ML. Sexual risk behaviours and STIs in drug abuse treatment populations whose drug of choice is crack cocaine. *Int J STD AIDS* 2002;13(11):769-774.
38. Adler-Storthz K, Dreesman GR, Kaufman RH, Melnick JL, Adam E. A prospective study of herpes simplex virus infection in a defined population in Houston, Texas. *Am J Obstet Gynecol* 1985;151(5):582-6.
39. Wald A, Zeh J, Selke S, Warren T, Ashley R, Corey L. Genital shedding of herpes simplex virus among men. *J Infect Dis* 2002;186 Suppl 1:S34-9.
40. Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. *Clin Infect Dis* 2002;34(7):944-8.
41. Watts DH, Brown ZA, Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. *Am J Obstet Gynecol* 2003;188(3):836-43.
42. Sucato G, Celum C, Dithmer D, Ashley R, Wald A. Demographic rather than behavioral risk factors predict herpes simplex virus type 2 infection in sexually active adolescents. *Pediatr Infect Dis J* 2001;20(4):422-6.
43. Hitti J, Watts DH, Burchett SK, et al. Herpes simplex virus seropositivity and reactivation at delivery among pregnant women infected with human immunodeficiency virus-1. *Am J Obstet Gynecol* 1997;177(2):450-4.

44. Wald A, Koutsky L, Ashley RL, Corey L. Genital herpes in a primary care clinic. Demographic and sexual correlates of herpes simplex type 2 infections. *Sex Transm Dis* 1997;24(3):149-55.
45. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. *N Engl J Med* 1997;337(8):509-15.
46. Oliver L, Wald A, Kim M, et al. Seroprevalence of herpes simplex virus infections in a family medicine clinic. *Arch Fam Med* 1995;4(3):228-32.
47. Koutsky LA, Ashley RL, Holmes KK, et al. The frequency of unrecognized type 2 herpes simplex virus infection among women. Implications for the control of genital herpes. *Sex Transm Dis* 1990;17(2):90-4.
48. Stamm WE, Handsfield HH, Rompalo AM, Ashley RL, Roberts PL, Corey L. The association between genital ulcer disease and acquisition of HIV infection in homosexual men. *Jama* 1988;260(10):1429-33.
49. Russell DB, Tabrizi SN, Russell JM, Garland SM. Seroprevalence of herpes simplex virus types 1 and 2 in HIV-infected and uninfected homosexual men in a primary care setting. *J Clin Virol* 2001;22(3):305-13.
50. Kent HE, Garland S, Carmody C, Denham I. Prevalence of type-specific herpes simplex virus antibodies in partners of patients with recurrent genital herpes. *Venereology* 2001;14(4):160-161.
51. Tideman RL, Taylor J, Marks C, et al. Sexual and demographic risk factors for herpes simplex type 1 and 2 in women attending an antenatal clinic. *Sex Transm Infect* 2001;77(6):413-5.
52. Cunningham AL, Lee FK, Ho DW, et al. Herpes simplex virus type 2 antibody in patients attending antenatal or STD clinics. *Med J Aust* 1993;158(8):525-8.
53. Gibney L, Macaluso M, Kirk K, et al. Prevalence of infectious diseases in Bangladeshi women living adjacent to a truck stand: HIV/STD/hepatitis/genital tract infections. *Sex Transm Infect* 2001;77(5):344-350.
54. Reynolds SJ, Risbud AR, Shepherd ME, et al. Recent herpes simplex virus type 2 infection and the risk of human immunodeficiency virus type 1 acquisition in India. *J Infect Dis* 2003;187(10):1513-1521.

55. Madhavan HN, Priya K. The diagnostic significance of enzyme linked immuno-sorbent assay for herpes simplex, varicella zoster and cytomegalovirus retinitis. *Indian J Ophthalmol* 2003;51(1):71-5.
56. Thomas K, Thyagarajan SP, Jeyaseelan L, et al. Community prevalence of sexually transmitted diseases and human immunodeficiency virus infection in Tamil Nadu, India: A probability proportional to size cluster survey. *Natl Med J India* 2002;15(3):135-140.
57. Hashido M, Lee FK, Nahmias AJ, et al. An epidemiologic study of herpes simplex virus type 1 and 2 infection in Japan based on type-specific serological assays. *Epidemiol Infect* 1998;120(2):179-86.
58. Kim O, Kim SS, Park MS, et al. Seroprevalence of sexually transmitted viruses in Korean populations including HIV-seropositive individuals. *Int J STD AIDS* 2003;14(1):46-49.
59. Sukvirach S, Smith JS, Tunsakul S, et al. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. *J Infect Dis* 2003;187(8):1246-1256.
60. Christensen PB, Engle RE, Jacobsen SEH, Krarup HB, Georgsen J, Purcell RH. High prevalence of hepatitis E antibodies among Danish prisoners and drug users. *J Med Virol* 2002;66(1):49-55.
61. Kjaer SK, de Villiers EM, Caglayan H, et al. Human papillomavirus, herpes simplex virus and other potential risk factors for cervical cancer in a high-risk area (Greenland) and a low-risk area (Denmark)--a second look. *Br J Cancer* 1993;67(4):830-7.
62. Kjaer SK, de Villiers EM, Haugaard BJ, et al. Human papillomavirus, herpes simplex virus and cervical cancer incidence in Greenland and Denmark. A population-based cross-sectional study. *Int J Cancer* 1988;41(4):518-24.
63. Arvaja M, Lehtinen M, Koskela P, Lappalainen M, Paavonen J, Vesikari T. Serological evaluation of herpes simplex virus type 1 and type 2 infections in pregnancy. *Sex Transm Infect* 1999;75(3):168-71.
64. Malkin JE, Morand P, Malvy D, et al. Seroprevalence of HSV-1 and HSV-2 infection in the general French population. *Sex Transm Infect* 2002;78(3):201-3.
65. Janier M, Lassau F, Bloch J, et al. Seroprevalence of herpes simplex virus type 2 antibodies in an STD clinic in Paris. *Int J STD AIDS* 1999;10(8):522-6.

66. Wutzler P, Doerr HW, Farber I, et al. Seroprevalence of herpes simplex virus type 1 and type 2 in selected German populations-relevance for the incidence of genital herpes. *J Med Virol* 2000;61(2):201-7.
67. Rabenau HF, Buxbaum S, Preiser W, Weber B, Doerr HW. Seroprevalence of herpes simplex virus types 1 and type 2 in the Frankfurt am Main area, Germany. *Med Microbiol Immunol (Berl)* 2002;190(4):153-60.
68. Suligoi B, Dorrucci M, Volpi A, Andreoni M, Zerboni R, Rezza G. Prevalence and determinants of herpes simplex virus type 2 infection in a cohort of HIV-positive individuals in Italy. *Sex Transm Dis* 2002;29(11):665-7.
69. Suligoi B, Calistri A, Cusini M, Palu G. Seroprevalence and determinants of herpes simplex type 2 infection in an STD clinic in Milan, Italy. *J Med Virol* 2002;67(3):345-8.
70. Gaytant MA, Steegers EA, van Laere M, et al. Seroprevalences of herpes simplex virus type 1 and type 2 among pregnant women in the Netherlands. *Sex Transm Dis* 2002;29(11):710-4.
71. Dukers NH, Bruisten SM, van den Hoek JA, de Wit JB, van Doornum GJ, Coutinho RA. Strong decline in herpes simplex virus antibodies over time among young homosexual men is associated with changing sexual behavior. *Am J Epidemiol* 2000;152(7):666-73.
72. Goossens VJ, Schreij G, van der Geest S, et al. A delay in CD4 cell response after initiation of highly active antiretroviral therapy is associated with the presence of anti-cytomegalovirus but not with anti-herpes simplex virus antibodies. *Aids* 2002;16(12):1682-4.
73. Roest RW, van der Meijden WI, van Dijk G, et al. Prevalence and association between herpes simplex virus types 1 and 2-specific antibodies in attendees at a sexually transmitted disease clinic. *Int J Epidemiol* 2001;30(3):580-8.
74. de Ory F, Pachon I, Echevarria JM, Ramirez R. Seroepidemiological study of herpes simplex virus in the female population in the autonomous region of Madrid, Spain. *Eur J Clin Microbiol Infect Dis* 1999;18(9):678-80.
75. Laubereau B, Zwahlen M, Neuenschwander B, Heininger U, Schaad UB, Desgrandchamps D. [Herpes simplex virus type 1 and 2 in Switzerland]. *Schweiz Med Wochenschr* 2000;130(5):143-50.

76. Narouz N, Allan PS, Wade AH, Wagstaffe S. Genital herpes serotesting: a study of the epidemiology and patients' knowledge and attitude among STD clinic attenders in Coventry, UK. *Sex Transm Infect* 2003;79(1):35-41.
77. Evans BA, Kell PD, Bond RA, MacRae KD, Slomka MJ, Brown DW. Predictors of seropositivity to herpes simplex virus type 2 in women. *Int J STD AIDS* 2003;14(1):30-6.
78. Cowan FM, Copas A, Johnson AM, Ashley R, Corey L, Mindel A. Herpes simplex virus type 1 infection: a sexually transmitted infection of adolescence? *Sex Transm Infect* 2002;78(5):346-8.
79. Cowan FM, Johnson AM, Ashley R, Corey L, Mindel A. Antibody to herpes simplex virus type 2 as serological marker of sexual lifestyle in populations. *Bmj* 1994;309(6965):1325-9.
80. Opaneye AA, Bashford J. Seroprevalence of antibodies to herpes simplex virus types 1 and 2 among two sexually active female populations in Middlesbrough, England. *J R Soc Health* 2002;122(2):108-11.